AstraZeneca's Iressa May Pave Way For EGFR Inhibitors In Adjuvant Lung Cancer
Executive Summary
Study done in China may prompt a change the standard of care in the US to include earlier testing for EGFR mutations after surgery, but is unlikely to change treatment protocols until overall survival data are available.